The event will discuss data from emerging OX40/OX40L inhibitors, including Inmagene’s IMG-007 - the only clinical-stage non-depleting anti-OX40 mAb. A live question and answer session will follow the ...
Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...